This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

26 Feb 2014

Novartis Extends Leadership in Clinical Trial Data Transparency, Reinforcing its Support of Clinical Research and Innovation

Novartis has announced additional steps to extend its leadership in clinical trial data transparency. Since 2005, and before requirements were in place, Novartis has been voluntarily disclosing summaries of Clinical Study Reports of its innovative medicines on its own website ( In addition, the company is committed to enhancing Clinical Study Report summaries for all new pivotal studies to include easy to understand consumer language summaries and additional interpretation of data as of the end of 2014.


Novartis has long supported data transparency and was the first company to publish positive and negative study results of its innovative medicines within one year of the study completion further enabling clinical research while protecting patient privacy.


To date, Novartis has registered 2720 trials on and published 559 trial results on the same site as well as 1777 clinical study summaries (known as "redacted clinical study reports"). Researchers can also now request access to patient level data on newly approved innovative medicines in 2014 through the same Idea Point portal as other pharmaceutical companies.


"Novartis has taken action to extend our leadership regarding clinical data transparency and access to data by researchers. This is designed to further advance science and innovation which can benefit patients," stated Tim Wright, Global Head of Development, Novartis Pharmaceuticals. "We also believe that patient rights and privacy remains paramount, and recognize that such data should not be released without the express consent of the patient".

Related News